Lower frequency of anti-citrullinated protein antibodies among early arthritis patients with high body mass index

Author information

CER12801
2020 Vol.38, N°6
PI 1155, PF 1160
Full Papers

purchase article

PMID: 32242805 [PubMed]

Received: 24/09/2019
Accepted : 20/01/2020
In Press: 28/03/2020
Published: 03/12/2020

Abstract

OBJECTIVES:
To investigate the role of body mass index (BMI) in the phenotypic and genotypic characteristics of early arthritis patients.
METHODS:
We analysed the clinical and laboratory parameters from the baseline visit of patients (670 patients [78.51% women]) included in the PEARL study. The WHO definition for low weight, normal weight, overweight and obesity (BMI <18.5, 18.5–25, 25–30 or ≥30 kg/m2, respectively) was applied. Anticitrullinated protein antibodies (ACPA) were studied by ELISA and HLA-DRB1* were genotyped by sequence speci c oligonucleotide probes. The relationship between BMI classification and other variables was analysed using Kruskall-Wallis, Anova and Chi-Square tests. Then multivariate logistic regression was performed to establish the role of BMI in ACPA positivity and ordered logistic regression to establish its relationship with ACPA level.
RESULTS:
Among the patients studied, 255 (38.06%) were considered overweight and 136 (20.3%) obese. High BMI patients had significantly more pain perception and disability than normal weight patients, whereas no clear differences in disease activity were observed between high BMI and normal weight patients. ACPA positivity was significantly less frequent in overweight and obese patients compared to normal BMI patients. This information was confirmed by adjusting for smoking habit and the presence of shared epitope.
CONCLUSIONS:
Our data support the theory that high BMI patients suffer more frequently from ACPA-negative RA. Nevertheless, although no disease activity differences were observed, these patients showed higher pain and disability scores since the beginning of disease.